Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Goldin

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
American Journal of Respiratory and Critical Care Medicine|July 10, 2018
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative AnalysisXiaoping Wu, Grace H Kim, Margaret L Salisbury, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Chest|April 11, 2020
The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner SocietyGeoffrey D Rubin, Christopher J Ryerson, Linda B Haramati, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|March 24, 2025
The Use of CT Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner SocietyRaúl San José Estépar, R Graham Barr, Sean B Fain, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
American Journal of Respiratory and Critical Care Medicine|January 4, 2024
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory AgencyGanesh Raghu, Marya Ghazipura, Thomas R Fleming, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
American Journal of Respiratory and Critical Care Medicine|July 10, 2018
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative AnalysisXiaoping Wu, Grace H Kim, Margaret L Salisbury, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Chest|April 11, 2020
The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner SocietyGeoffrey D Rubin, Christopher J Ryerson, Linda B Haramati, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|March 24, 2025
The Use of CT Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner SocietyRaúl San José Estépar, R Graham Barr, Sean B Fain, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
American Journal of Respiratory and Critical Care Medicine|January 4, 2024
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory AgencyGanesh Raghu, Marya Ghazipura, Thomas R Fleming, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 11